Shenzhen Chipscreen Biosciences (688321) News

Two data points for China's innovative drug sector hit record highs in 2025, unveiling high-growth potential concept stocks.

Gelonghui January 13 | The National Medical Products Administration announced on January 3 that the development of innovative drugs in China reached a new level in 2025: A total of 76 innovative drugs were approved for marketing during the year, significantly increasing from 48 in 2024. Meanwhile, the total value of overseas licensing transactions for innovative drugs exceeded 1.3 trillion US dollars, with more than 150 deals completed, setting new records for both figures. By category, among the 76 innovative drugs approved in 2025, 47 were chemical drugs, 23 were biological products, and 6 were traditional Chinese medicines. Notably, domestically produced innovative drugs performed exceptionally well: Of these, 38 chemical drugs and 21 biological products were domestically produced, accounting for

Gelonghui FinanceJan 13 12:31

Undercurrents of Capital: Major Leadership Changes Expected in Pharmaceutical Listed Companies by 2025

Rivers and Lakes, Capital, Stories. According to Cai Jun of The Investor newspaper, the senior management changes in pharmaceutical listed companies in 2025 reveal a new signal: iteration. Incomplete statistics show that about 10 companies with market capitalizations of approximately 10 billion yuan have adjusted their upper management levels. Among these enterprises, some founders have stepped back to take secondary roles, successors from the second generation have taken over, and changes have been driven by shareholder intentions. Capital operations are intertwined in these transitions, making the leading figures on this stage appear even more distinct. As old faces retreat and new ones emerge, wherever there are people, there are rivers and lakes, capital, and stories. Generally speaking, adjustments to senior executives of listed companies tend to concentrate around mid-year or year-end. In 2025, such occurrences have clustered more frequently towards the end of the year.

China InvestorsJan 10 08:01

Chipscreen Biosciences Gets Nod for Xioronni Capsules' Clinical Trials

MT NewswiresJan 9 16:15

Shenzhen Chipscreen Biosciences Gets Macao Marketing Approval for Cancer Drug

MT NewswiresJan 8 18:24

Micrux Biotech (688321.SH): Chiaurine Capsule Receives Approval Notice for Clinical Drug Trial

Gelonghui, January 8th - Chipscreen Biosciences (688321.SH) announced that the company has recently received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration, approving the clinical trial of the company's product, Chiaurinib Capsules. Chiaurinib is a novel small-molecule anti-tumor drug independently developed by the company with global intellectual property protection. It features a multi-pathway mechanism of action against tumors by inhibiting multiple kinase targets such as Aurora B, CSF1R, and VEGFR/PDGFR/c-Kit, exerting comprehensive anti-pancreatic cancer effects. Chiaurinib achieves

Gelonghui FinanceJan 8 15:37

Express News | Chipscreen Biosciences: Tucidinostat Tablets Approved for Marketing in Macao

BreakingsJan 7 16:19

Chipscreen Biosciences (688321.SH): The Macao Drug Administration has approved the listing of Chidamide.

On January 7, Microcore Bio (688321.SH) announced that the official website of the Drug Administration Bureau of the Macao Special Administrative Region of the People's Republic of China (hereinafter referred to as "ISAF") has disclosed that ISAF has approved the listing of the company’s Chidamide tablets. Chidamide (trade name: EpiDaza/Aipusha) is the world's first subtype-selective histone deacetylase (HDAC) inhibitor. It pioneered the licensing out of Chinese innovative drugs to Europe and the United States. Chidamide has already been approved in mainland China for the treatment of peripheral T-cell lymphoma.

Gelonghui FinanceJan 7 16:19

Express News | Microrna Biotech: Clinical trial application for miglitol metformin sustained-release tablets accepted

BreakingsJan 5 18:06

Chinese Drug Regulator Accepts Clinical Trial Application of Chipscreen Biosciences' Unit for CS08399 Tablets

MT NewswiresJan 2 13:04

Express News | Micrux Biotech: Clinical trial application for CS08399 tablets accepted.

BreakingsDec 31, 2025 17:35

Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences Named the Chinese Mainland Winner of the EY Entrepreneur Of The Year 2025 Awards

PR NewswireDec 30, 2025 08:45

Microchip Biotech (688321.SH): Appointment of Li Jianxun as General Manager

Gelonghui, December 23rd – Chipscreen Biosciences (688321.SH) announced that, in light of the company’s actual operational development needs and after the Board Nomination Committee reviewed and approved the qualifications, the company convened the 19th meeting of the Third Board of Directors on December 23, 2025. The meeting deliberated and passed the proposals 'Regarding the Appointment of the Company’s General Manager' and 'Regarding the Change of the Company’s Legal Representative.' The Board agreed to appoint Mr. Jianxun Li as the company’s General Manager, with a term starting from the date this proposal was approved by the Board until the end of the term for the Third Board of Directors. According to Article 8 of the 'Articles of Association of the Company,' regarding 'the legal representative of the company...'

Gelonghui FinanceDec 23, 2025 20:25

Microchip Biotech (688321.SH): Cumulative repurchase of 538,200 company shares

Gelonghui, December 23rd - Microcore Bio (688321.SH) announced that as of December 23, 2025, the company has completed this share repurchase. Through the Shanghai Stock Exchange trading system, the company repurchased a total of 538,200 shares via centralized bidding, accounting for 0.13% of the company's total share capital. The highest price per share was RMB 29.05, and the lowest price per share was RMB 26.8. The total amount paid was RMB 14.9967 million (excluding stamp duty, transaction commissions, and other fees).

Gelonghui FinanceDec 23, 2025 20:23

Express News | Chipscreen Biosciences: Tucidinostat Tablets Included in the National Medical Insurance Catalog

BreakingsDec 7, 2025 16:53

Microchip Biotech (688321.SH): No Company Shares Repurchased Yet

Gelonghui, December 1 — Microcore Biotech (688321.SH) announced that as of November 30, 2025, the company had not yet repurchased its shares through the Shanghai Stock Exchange's centralized bidding system.

Gelonghui FinanceDec 1, 2025 17:28

Microchip Biotech (688321): Rapid advancement in innovative pipeline drives steady revenue growth.

Event: From January to September 2025, the company's operating revenue increased by 40.12%, primarily due to further growth in sales revenue from the company’s products, Chidamide and Ciglitazone Sodium. Notably, Chidamide’s sales revenue grew year-on-year.

Huaxi SecuritiesNov 27, 2025 19:18

Microchip Biotech (688321.SH): Shareholder Bio-Orient Biotech Completes 3% Reduction in Company Shares

Gelonghui, November 26th丨SciClone Pharmaceuticals (688321.SH) announced that on November 26, 2025, the company received a notification letter titled "Notice of Equity Change Reaching 1% Threshold and Completion of Share Reduction Plan" from its shareholder BioChain Biotech. Between October 14, 2025, and November 26, 2025, BioChain Biotech reduced its holdings in the company by a total of 12.2339 million shares through centralized bidding and block trading, representing 3% of the company’s total shares. This share reduction plan has now been fully implemented.

Gelonghui FinanceNov 26, 2025 17:49

Targeting fields such as cell and gene therapy, and brain-computer interfaces! Shanghai's new pharmaceutical policies unleash multiple benefits, with innovative drugs and medical devices becoming the focal point.

In recent days, multiple brokerage research institutions have issued research reports expressing optimism about innovative medical devices and the innovative pharmaceuticals industry chain.

China SecuritiesNov 24, 2025 21:28

Microchip Biotech (688321.SH): BioChain Biotech has cumulatively reduced its stake by 4,829,500 shares in the company.

Gelonghui, November 19th: Chipscreen Biosciences (688321.SH) announced that from October 23, 2025, to November 19, 2025, CapitalBio Corporation reduced its holdings in the company by a total of 4.8295 million shares through competitive bidding and block trading. As a result, the combined shareholding of CapitalBio Corporation and Tianfu Tsinghua decreased from 40,799,072 shares to 35,969,608 shares, and their combined shareholding percentage dropped from 10.00% before the change in equity interest to 8.82%. The change in equity interest reached the 1% threshold.

Gelonghui FinanceNov 19, 2025 20:25

Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment

MT NewswiresNov 7, 2025 18:05